Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Extension of LMIS 50 mg in Advanced Prostate Carcinoma
NCT02712320Phase 3Completed
- Sponsor
- Foresee Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- May 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of leuprolide in prostate carcinoma, sponsored by Foresee Pharmaceuticals. Primary endpoints: Number of Participants With Adverse Events up to 48 weeks, Evaluate the Effect of LMIS 50 mg on Cardiovascular Function up to 48 weeks and 3 more. Started Feb 2016; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate carcinoma
Beyond the preview
Go deeper on NCT02712320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02712320.